Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a re-appraisal.

摘要: Oral factor Xa inhibitors are an attractive class of anticoagulants expected to have broad application. Rapid and reliable reversal the anticoagulant effect is important for patients with bleeding complications or those in need urgent procedures. While no specific agent yet available, multiple published clinical guidelines suggest that four-factor prothrombin complex concentrates (PCC) should be considered when desired. This presentation updates prior reviews on this topic (Crit Care, 17, 2013, 230; Thromb Haemost, 111, 2014, 189; J Thrombolysis, 2015, 39, 395); summarizes more recent evidence human studies indicating PCCs available North America do not reverse oral Xa-inhibitor anticoagulants. New agents horizon appear far promising as therapies inhibitors.